Odronextamab
Ordspono · Bispecific (CD20×CD3)
CD20×CD3 bispecific; tumor-lysis urate crystal nephropathy with CRS.
BCMA×CD3 bispecific T-cell engager
Lynozyfic · BCMA×CD3 engager
BCMA×CD3 bispecific T-cell engager · approved 2025 · 6 citations
Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.
T-cell redirection, not tubular poison — AKI rides on cytokine release, not the drug itself.
Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.
Signature lesion
No drug-specific renal toxicity signal was reported in the LINKER-MM1 registrational program; AKI is not a labeled or characteristic adverse event. Any kidney injury is expected to be indirect and infrequent, mediated chiefly by cytokine release syndrome (CRS), infection/sepsis, and (early) tumor lysis. By class analogy to CAR-T and other immune-effector therapies, AKI occurs in roughly 5-21% of T-cell-redirection recipients, is usually mild (KDIGO stage 1) and transient with recovery in ~79% within a month, and tracks with higher-grade CRS. No linvoseltamab-specific incidence is published.Source: No linvoseltamab-specific renal incidence reported in LINKER-MM1 (Bumma 2024, PMID 38879802; Lee 2025, PMID 41387038). Class-level AKI estimates (~5-21%, mostly transient, CRS-associated) extrapolated from CAR-T/immune-effector cohorts (León-Román 2024, PMID 38500492; Rousseau 2024, PMID 36220698).
Days — coincident with step-up dosing and CRS in the first 1–2 weeks.
Distilled from: “Days — coincident with step-up dosing and CRS in the first 1-2 weeks; CRS in LINKER-MM1 occurred predominantly during step-up dosing.”
This agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.
Renal hypoperfusion from capillary leak and cytokine storm — IL-2 and CAR-T cytokine release syndrome.
Intratubular precipitation of drug or metabolite — high-dose methotrexate and tumor lysis crystals.
Renal electrolyte derangement — magnesium/potassium/calcium wasting (cisplatin, anti-EGFR antibodies) or retention (FGFR-inhibitor hyperphosphatemia, tumor-lysis hyperkalemia/hyperphosphatemia).
Tap a signature to trace where it strikes the nephron.
Functional / pre-renal — reduced perfusion upstream of the nephron; no single structural segment is injured.
Prerenal / Hemodynamic AKI: functional / pre-renal, no single structural segment injured.
Prerenal / Hemodynamic AKI
Renal hypoperfusion from capillary leak and cytokine storm — IL-2 and CAR-T cytokine release syndrome.
Linvoseltamab is a fully human IgG4-based bispecific antibody that simultaneously binds B-cell maturation antigen (BCMA/TNFRSF17) on malignant plasma cells and CD3 on T cells, forming an immunologic synapse that redirects polyclonal cytotoxic T cells to lyse myeloma cells independent of MHC restriction. Bridging triggers T-cell activation, proliferation, and release of perforin/granzyme and inflammatory cytokines, producing deep and durable myeloma responses.
Class-level context for the major non-renal toxicities of the BCMA×CD3 bispecific T-cell engager class.
Immune / Infusion
CRS, infusion reactions, irAEs, anaphylaxis
Neurologic
Neuropathy, encephalopathy, ICANS, PRES
Hematologic
Cytopenias, thrombosis, TMA
6 primary references — trials, cohorts, mechanism, and reviews. Citation metadata via PubMed / NLM.
Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.
Everything below is FAERS — adverse events someone chose to report, about 53 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.
Reported with a death outcome
4 of 53 reports
Reported with hospitalization
17 of 53 reports
Reports per year
Reports received per year, 2015–2026 · most recent year is partial.
Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-11-15.
Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.
General onco-nephrology references
Where Linvoseltamab sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.
Ordspono · Bispecific (CD20×CD3)
CD20×CD3 bispecific; tumor-lysis urate crystal nephropathy with CRS.
Jaypirca · Non-covalent BTK inhibitor
2023 BTK inhibitor; tumor lysis risk.
Zevalin · Radioimmunotherapy (Y-90 anti-CD20)
Yttrium-90 radioimmunotherapy; tumor lysis with bulky lymphoma.
Leustatin · Purine analog
Tumor lysis; high-dose nephrotoxicity.
Etopophos · Topoisomerase II inhibitor
Tumor lysis; renally cleared.
Hydrea · Ribonucleotide reductase inhibitor
Tumor lysis in myeloproliferative disease.
Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.
Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile. Agents sharing a number are tied on all three. An agent marked FAERS n/a has too few reports to test, so its place rests on severity and injury breadth alone.
A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.